TNF-alpha antagonists: Benefits beyond remission

Reviews in Gastroenterological Disorders

Volumn 7, Issue SUPPL. 1, 2007, Pages

  Mahadevan, Uma ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adalimumab; Certolizumab pegol; Crohn's disease; Infliximab

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACNE; ANXIETY; AVASCULAR NECROSIS; CLINICAL TRIAL; COLON FISTULA; COLON MUCOSA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; HOSPITALIZATION; HUMAN; INFECTION; IRRITABILITY; MOON FACE; OSTEOPOROSIS; REMISSION; REVIEW; SIDE EFFECT; WATER RETENTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 33847684273     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Hanauer SB, Feagan BG, Liechtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
2. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
3. Sandborn W, Feagan BG, Stoinov S, et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled phase III study (PReCiSE I) [abstract]. Gastroenterology. 2006;130(4 suppl 2): A-107.
4. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77(4 pt 2):847-869.
5. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656.
6. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
7. Lichtenstein G, Cohen R, Reagan B, et al. Safety of infliximab and other Crohn's disease therapies-TREAT registry data with nearly 15,000 patient years of follow up [abstract]. Gastroenterology. 2006;130(4 suppl 2):A-71.
8. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130:1054-1061.
9. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
10. Hommes D, Baert F, van Assche G, et al. The ideal management of Crohn's disease: top down versus step up strategies, a randomized controlled trial [abstract]. Gastroenterology. 2006;130(4 suppl 2): A-108.
11. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875-880.
12. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
13. Hinojosa J, Gomollon F, Nos P, et al. Four-week results of adalimumab treatment in subjects with fistulizing Crohn's disease who have failed response or showed intolerance to infliximab [abstract]. Gastroenterology. 2006;130(4 suppl 2):A-120.
14. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442; quiz 464.
15. D'Haens G, Hommes D, Baert F, et al. A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease [abstract]. Gastroenterology. 2006;130 (4 suppl 2):A-110.
16. Irvine FJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287-296.
17. Feagan BG, Yan S, Bala M, et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol. 2003;98:2232-2238.
18. Rutgeerts P, Melili L, Li J, et al. Adalimumab maintains improvement in Inflammatory Bowel Disease Questionnaire (IBDQ) scores over 1 year following the initial attainment of remission in patients with moderately to severely active Crohn's disease [abstract]. Gastroenterology. 2006;130(4 suppl 2):A-479.
19. Schreiber S, Khaliq-Kareemi M, Lawrance I, et al. Certolizumab pegol, a humanised anti-TNF pegylated FAb′ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (Precise). Gut. 2005;54(suppl VII): A82.
20. Feagan BG, Bala M, Yan S, et al. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol. 2005;39:390-395.
21. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
22. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-869.